EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2026

EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2026

Summary
Multiple sclerosis (MS) is an autoimmune disease affecting principally the central nervous system that causes nerve sheath demyelination followed by axon damage and paralysis. MS symptoms include muscle weakness, weak reflexes, tremor, muscle spasm, prolonged double vision, slurred speech, and balance problems. It can occur at any age, but commonly affects people of ages 15-60 years. Women are about twice as likely as men to develop this disease (Mayo Clinic, 2016). MS symptoms may occur and disappear completely, while the permanent neurological problems occur when the disease advances.

Our epidemiologists forecast that the diagnosed prevalent cases of MS in the 7MM will grow by an Annual Growth Rate (AGR) of almost 0.8% per year over the next 10 years, from around 1 million cases in 2016 to around 1.1 million cases in 2026. Of the 7MM, the US had the highest number of diagnosed prevalent cases with around 0.4 million cases in 2016, while Japan had the lowest number of diagnosed prevalent cases with almost 20,000 cases in 2016. In 2016, the US accounted for around 40% of all the diagnosed prevalent cases of MS, while Japan accounted for only about 2% of diagnosed prevalent cases of MS in the 7MM.

Our epidemiologists forecast that the diagnosed incident cases of MS in the 7MM will grow by an AGR of around 0.3% per year over the next 10 years, from around 49,000 cases in 2016 to just over 50,000 cases in 2026. Additionally, the US will have the highest AGR of almost 0.8%, while Italy will have the lowest at negative rate of around 0.5%. From the 7MM, the US had the highest number of diagnosed incident cases of MS with over 20,000 cases in 2016, while Japan had the lowest number of diagnosed incident cases of MS with nearly 1,000 cases in 2016. In 2016, the US accounted for over 42% of all the MS cases, while Japan accounted for only about 2% of diagnosed incident cases of MS in the 7MM.

The report "EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and the global and historical trends for MS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the diagnosed prevalent and diagnosed incident cases of MS, segmented by sex and by age (for all ages) in these markets. The diagnosed prevalent cases are further segmented by types of MS (relapsing-remitting [RRMS], primary progressive [PPMS], and secondary progressive [SPMS]) in the 7MM.

Scope
- The Multiple sclerosis (MS) EpiCast Report provides an overview of the risk factors and global trends for MS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the diagnosed prevalent and diagnosed incident cases of MS, segmented by sex and by age (for all ages) in these markets. The diagnosed prevalent cases are further segmented by types of MS (relapsing-remitting [RRMS], primary progressive [PPMS], and secondary progressive [SPMS]) in the 7MM.
- The MS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy
The MS EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global MS market.
- Quantify patient populations in the global MS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MS therapeutics in each of the markets covered.
- Understand magnitude of MS population by disease type.